top of page
Akero Therapeutics
Sponsored by Akero Therapeutics, our metabolic associated steatohepatitis (MASH, formerly known as NASH/fatty liver) study is a phase 3, randomized, double blind, placebo-controlled study evaluating the safety and efficacy of Efruxifermin (EFX) with once weekly dosing for a period of up to 96 weeks. EFX could help send the right signals to the liver and fat tissues, allowing the body's metabolism to work more efficiently.
This study is for patients with MASH and will involve a biopsy to determine study eligibility.
Apply or Inquire
To Apply or Inquire
Enter your information and press the 'Submit' button
or Call Dr. Jay
415-353-0800
GSK Study
Phase 2b Study of GSK4532990 in Adults with NASH
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of
GSK4532990 in Adults with Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH).
GSK4532990 is a medicine that uses synthetic RNA to reduce the production of a liver protein
called HSD17B13. This is expected to protect the liver, similar to a natural genetic condition that
has a safeguarding effect.
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced (F3) fibrosis.
Study details include:
• The study duration will be up to 76 weeks including the screening period.
• The treatment duration will be up to 52 weeks.
https://classic.clinicaltrials.gov/ct2/show/NCT05583344
bottom of page